Adipose-derived mesenchymal stem cells promote the survival of fat grafts via crosstalk between the Nrf2 and TLR4 pathways

Xiaosong Chen¹,², Liu Yan¹,², Zhihui Guo¹, Zhaohong Chen³, Ying Chen¹,², Ming Li¹, Chushan Huang¹, Xiaoping Zhang⁴ and Liangwan Chen∗,⁵

Autologous fat grafting is an effective reconstructive surgery technique; however, its success is limited by inconsistent graft retention and an environment characterized by high oxidative stress and inflammation. Adipose-derived stem cells (ADSCs) increase the survival of fat grafts, although the underlying mechanisms remain unclear. Here, TLR4−/− and Nrf2−/− mice were used to explore the effects of oxidative stress and inflammation on the viability and function of ADSCs in vitro and in vivo. Enrichment of fat grafts with ADSCs inhibited inflammatory cytokine production, enhanced growth factor levels, increased fat graft survival, downregulated NADPH oxidase (NOX)1 and 4 expression, increased vascularization and reduced ROS production in a manner dependent on toll-like receptor (TLR)-4 and nuclear factor erythroid 2-related factor 2 (Nrf2) expression. Immunohistochemical analysis showed that exposure to hypoxia enhanced ADSC growth and promoted the differentiation of ADSCs into vascular endothelial cells. Hypoxia-induced inflammatory cytokine, growth factor and NOX1/4 upregulation, as well as increased ROS production and apoptosis in ADSCs were dependent on TLR4 and Nrf2, which also modulated the effect of ADSCs on promoting endothelial progenitor cell migration and angiogenesis. Western blot analyses showed that the effects of hypoxia on ADSCs were regulated by crosstalk between Nrf2 antioxidant responses and NF-κB- and TLR4-mediated inflammatory responses. Taken together, our results indicate that ADSCs can increase the survival of fat transplants through the modulation of inflammatory and oxidative responses via Nrf2 and TLR4, suggesting potential strategies to improve the use of ADSCs for cell therapy.

Cell Death and Disease (2016) 7, e2369; doi:10.1038/cddis.2016.261; published online 8 September 2016

Autologous fat grafting, which is the transfer of subcutaneous fat from a donor site to a recipient site, is a commonly used procedure in both cosmetic and reconstructive surgery. However, the success of fat grafting is limited by the unpredictability of long-term graft retention, with a reported resorption rate of 10–90%. After enzymatic processing, harvested fat contains a mix of adipose-derived stem cells (ADSCs), vascular progenitor cells, endothelial cells and pericytes. The enrichment of grafted tissue with ADSCs, which are multipotent cells that can be induced to differentiate into many lineages, including adipogenic, chondrogenic, myogenic and osteogenic cells, is one of the most efficient techniques to improve the survival rate of fat grafts. In addition, appropriate revascularization is an important factor determining graft survival, and new angiogenesis from the host vascular network is responsible for graft revascularization. Engrafted ADSCs are also susceptible to cell death in an environment characterized by inflammation and oxidative stress.

Oxidative stress affects ADSCs and their regenerative capacity, and dysregulation of reactive oxygen species (ROS) production impairs ADSC expansion in vitro and the viability of engrafted ADSCs. However, low levels of ROS were shown to activate cellular processes involved in the normal physiological function of stem cells. Intracellular ROS are generated by the action of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase enzymes (NOX) and passively by mitochondria. Culture of ADSCs under hypoxic conditions increases their proliferative and migratory capacities and enhances the secretion of growth factors. There are four NOX enzymes, of which NOX4 is predominantly expressed in ADSCs and modulates ROS signaling as well as the proliferation and differentiation of ADSCs. Toll-like receptors (TLRs) are pattern recognition receptors that respond to infection by recognizing pathogen-associated molecular patterns, triggering immune responses against invading micro-organisms. Twelve members of the TLR family have been identified in mammals, of which TLR4 is expressed on the cell surface. Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcriptional factor involved in cellular defenses against oxidative stress. Under normal conditions, Nrf2 localizes to the cytoplasm and binds to...
Kelch-like ECH-associated protein 1 (Keap-1), which mediates its proteasomal degradation, whereas Nrf2 activation induces its translocation to the nucleus to promote the transcription of target genes. Nrf2 activation promotes cell survival and protects against oxidative stress-induced damage, whereas disruption of Nrf2 signaling impairs the angiogenic capacity of endothelial cells and antioxidant gene expression, and enhances oxidative stress-mediated inflammation. Nrf2 regulates the expression of many antioxidant genes, including heme oxygenase-1 (HO-1), an antioxidant enzyme, through consensus cis-elements termed antioxidant-response elements.

In the present study, TLR4−/− and Nrf2−/− mice were used to explore the effects of oxidative stress and inflammation on the viability and function of ADSCs and their role in improving the survival of fat grafts in vitro and in vivo.

Results

Effect of TLR4 and Nrf2 on inflammatory cytokine and growth factor secretion in ADSCs. The effect of ADSC agonists on the secretion of inflammatory cytokines and growth factors was examined by measuring the levels of IL-6, TNF-α, IL-1β, VEGF and bFGF in the serum of mice with or without fat grafts 2 weeks after transplantation by ELISA. The results showed that addition of ADSCs attenuated inflammatory cytokine production and enhanced VEGF and bFGF production in mice receiving fat grafts (Figures 1a–e). The ADSC-induced decrease in inflammatory cytokines was enhanced by TLR4 deletion and partially restored by Nrf2 knockout (Figures 1a–c), whereas the ADSC-induced upregulation of growth factors was inhibited in TLR4−/− mice and partly restored in Nrf2−/− mice. Taken together, these results indicated that ADSCs modulate the changes in inflammatory cytokines and growth factors in fat grafts via a mechanism involving TLR4 and Nrf2.

Effect of Nrf2 or TLR4 on ADSC-mediated survival of fat grafts. The survival of fat grafts was assessed in control and TLR4 or Nrf2 knockout mice receiving adipose tissues enriched with ADSCs. The results showed that ADSCs promoted the survival of fat grafts, whereas this effect was significantly decreased in Nrf2 and TLR4 knockout mice, in which grafts did not survive after 2 months in the absence of ADSCs (Figures 2a and b). Analysis of NOX1, NOX4 and HO-1 expression in transplanted adipose tissues by real-time PCR 2 weeks after transplantation showed that ADSCs downregulated NOX1 and NOX4 in mice receiving fat grafts, and this effect was enhanced by TLR4 knockout, whereas it was suppressed by Nrf2 knockout, which restored NOX1/4 levels to those observed in mice receiving untreated fat grafts (Figures 2c and d). ADSCs significantly upregulated HO-1, and this effect was enhanced by TLR4 deletion, whereas it was suppressed by Nrf2 deletion (Figure 2e). Hematoxylin and eosin staining of fat grafts 2 weeks after transplantation showed that addition of ADSCs increased the capillarization of fat tissues, whereas the increase in capillary density was decreased by TLR4 or Nrf2 knockout (Figure 2f). Quantification of the number of capillaries showed that ADSCs caused an approximately fourfold increase in the number of capillaries in adipose tissues, and this effect was partially restored in TLR4 and Nrf2 knockout mice (Figure 2g). In addition, Nrf2 and to a lesser extent TLR4 knockout increased ROS generation in adipose tissues 2 weeks after transplantation, whereas ADSC treatment partially suppressed this effect, restoring ROS levels (Figure 2g).

Differentiation of ADSCs into vascular endothelial cells. To determine the origin of endothelial cells (isolation and identification of endothelial progenitor cells (EPCs) were seen in Supplementary Figure S8) in surviving transplanted fat tissue, transplant sections were stained for the endothelial cell marker CD31 and analyzed by immunofluorescence.

Figure 1 Effect of ADSC agonists on inflammatory cytokine and growth factor secretion in mice undergoing fat transplants. (a–e) The levels of TNF-α, IL-1β and IL-6, VEGF, and bFGF were measured by ELISA in the serum of wild-type (WT), TLR4−/− and Nrf2−/− mice with or without fat grafts and with or without the addition of ADSCs 2 weeks after transplantation (n = 5). *P < 0.05, **P < 0.01, ***P < 0.001 versus control. (d and e) Concentration of VEGF and bFGF in serum was also detected by ELISA (n = 5). ***P < 0.001 versus control group. Control, WT mice without fat graft.
GFP-labeled ADSCs (Supplementary Figure S9) were detected in capillary-like structures and surrounding mature adipose tissue, as were CD31 and vWF stained neovascular capillary endothelial cells (stained in blue; Figure 3). Merging of images indicated the endothelial cells that had differentiated from GFP-labeled ADSCs, whereas the lack of co-localization of green and blue fluorescence indicated the potential differentiation of endothelial cells from EPCs.

Effect of hypoxia on cell growth and differentiation.

Isolated ADSCs were labeled with different cell surface markers to determine cell phenotypes. ADSCs were positive for the mesenchymal stem cell (MSC) markers CD29, CD90, CD44 and CD105 and negative for the endothelial markers CD34 and vWF (Figure 4a). Figure 4b shows representative phase contrast images of ADSCs cultured under normoxic or hypoxic conditions for different times, which indicated that hypoxia promoted the growth of ADSCs. To determine the differentiation potential of ADSCs under different conditions, ADSCs were cultured under adipogenic, endothelial or osteogenic induction conditions and stained with Oil-red O and ALP. The results showed that hypoxia promoted the adipogenic and osteogenic differentiation potential of ADSCs at 1 and 3 weeks of culture (Figures 4c and d). Quantitative
analysis was performed by measuring the absorbance of isolated fatty drops and by ALP activity assay, which confirmed that hypoxia increased the adipogenic and osteoblastic differentiation of ADSCs (Figures 4c and d). The endothelial differentiation of ADSCs was examined by immunofluorescence analysis of cells stained against vWF, which showed that hypoxia accelerated the differentiation of ADSCs into endothelial cells at 1 week (Figure 4e). ADSCs also induced tube formation from EPCs under hypoxic conditions and delayed the regression of capillary tubes on day 5, as determined using an *in vitro* angiogenesis assay and measurement of tube length (Figures 4f and g). Taken together, these results indicate that low oxygen tension increases the multipotent differentiation potential of ADSCs and suggest that ADSCs affect angiogenesis.

**Modulation of hypoxia-induced inflammatory cytokine, growth factor and ROS generation by Nrf2 and TLR4.** We further examined the effect of Nrf2 and TLR4 on the release of inflammatory cytokines and growth factors from ADSCs isolated from WT, Nrf2−/− or TLR4−/− mice exposed or not to hypoxic conditions. Western blot analysis showed that the upregulation of TNF-α, IL-1β and IL-6 caused by hypoxia was enhanced by Nrf2 deletion, whereas it was significantly inhibited by TLR4 deletion (Figure 5a). Hypoxia induced the upregulation of bFGF and VEGF, and this effect was suppressed by the deletion of both Nrf2 and TLR4 (Figure 5b). Figure 5c shows representative images of DCF-DA-stained transplanted fat tissue sections for the detection of ROS. To quantify the changes in ROS levels in response to hypoxia, mitochondrial DCF fluorescence intensity was measured in ADSCs, which showed that hypoxia increased ROS generation, and this effect was enhanced by Nrf2 deletion and suppressed by TLR4 deletion (Figure 5d). Western blot analysis of ADSC lysates showed that TLR4 knockout suppressed, whereas Nrf2 knockout enhanced the hypoxia-induced upregulation of NOX1 and NOX4; however, both deletion of TLR4 and Nrf2 suppressed hypoxia-induced HOX-1 upregulation (Figures 5e and f). Taken together, these results suggested that the effects of hypoxia on the
expression of inflammatory cytokines, growth factors and ROS generation were modulated by Nrf2 and TLR4. Nrf2 and TLR4 modulate ADSC apoptosis and ADSC-induced angiogenesis under conditions of hypoxia.

Detection of apoptosis by Annexin V/PI staining and flow cytometry and quantification of the rate of apoptosis showed that the increase in the rate of apoptosis induced by hypoxia was significantly enhanced by Nrf2 deletion and suppressed by TLR4 knockout (Figures 6a and b). Consistently, western blotting and densitometric quantification of bands showed that hypoxia increased the levels of cleaved caspase-3, indicating the induction of apoptosis, and this effect was significantly enhanced by Nrf2 deletion, whereas it was suppressed by TLR4 deletion (Figure 6c). Taken together, these results suggest that hypoxia-induced apoptosis in ADSCs is modulated by Nrf2 and TLR4. The chemotaxis of EPCs was assessed by measuring the migration of cells towards basal medium (endothelial basal medium (EBM)) or ADSC conditioned medium and tube formation, which are key steps involved in angiogenesis. The results showed that the increased migration of EPCs towards ADSC paracrine factors induced by hypoxia was suppressed significantly by deletion of Nrf2 and TLR4, with an approximately 50%
inhibition of EPC migration in the TLR4−/− group compared with the control (Figures 6d and e). Consistently, tube formation in EPCs was induced by ADSC conditioned medium under hypoxia, and this effect was significantly suppressed by Nrf2 or TLR4 knockout (Figures 6f and g). Taken together, these results indicate that the effect of ADSCs on promoting angiogenesis under hypoxia is modulated by Nrf2 and TLR4.

The mechanism of ADSCs promote the survival of fat grafts
Effect of hypoxia on the Keap-1/Nrf2/HO-1 and TLR4/ NFKB signaling pathways in ADSCs. TLRs act as sensors that detect microbial signals and elicit innate immune responses, and TLR signaling results in the activation of the transcription factor nuclear factor-κB (NF-κB) and the subsequent activation of inflammatory cytokine genes.17 We therefore examined the effect of Nrf2 and TLR4 on the TLR4/ NF-κB pathway under conditions of hypoxia by western blotting. The results showed that the upregulation of TLR4, MyD88 (a TLR4 adaptor), TRAF6 (a ring-domain E3 ubiquitin ligase that mediates the translocation of NF-κB to the nucleus), the NF-κB p65 subunit, and PI-κBα induced by hypoxia was significantly enhanced by Nrf2 knockout (Figures 7a–f). Conversely, silencing of NF-κB (Supplementary Figure S10) significantly upregulated HO-1 under conditions of hypoxia and maintained hypoxia-induced Keap-1 degradation (Figures 7g and h). NF-κB knockdown significantly promoted the translocation of Nrf2 from the cytoplasm to the nucleus under conditions of hypoxia (Figures 7i and k). Taken together, these results indicated that hypoxia promoted Nrf2 translocation to the nucleus and the upregulation of HO-1 via the inhibition of NF-κB nuclear translocation in ADSCs. Figure 7l shows a schematic describing the potential mechanism underlying the roles of Nrf2 and TLR4 on the enhanced survival of ADSCs under hypoxic conditions.

Discussion
ADSCs are considered an important source of stem cells for tissue repair and regeneration and have been shown to increase the survival of fat grafts.4 Culture of ADSCs under hypoxic conditions increases their regenerative potential, and this effect was shown to be mediated in part by the stimulatory effect of ROS.11,18 In addition, ADSCs are exposed to hypoxia and inflammation after transplantation, and understanding the effects of the inflammatory and hypoxic environment on ADSC viability is important to assess their effect on fat transplants. Here, we used TLR4−/− and Nrf2−/− mice to explore the mechanisms underlying the effect of ADSC enrichment on the survival of fat grafts in vivo and in vitro.

The results of the present study showed that ADSCs increased the survival of fat grafts after 2 months and this effect was attenuated in TLR4−/− and Nrf2−/− mice. The addition of ADSCs downregulated NOX1 and NOX4, and upregulated HO-1, and these effects were dependent on Nrf2 expression, indicating that the protective effect of Nrf2 against oxidative stress was mediated by the modulation of HO-1 and NOX1/4 expression. Nrf2 acts as a sensor of oxidative stress and therefore plays an important role in redox homeostasis and in the protection of cells against toxic insults and pathogen-associated diseases.19 However, Nrf2 activation is frequently present in cancer, and pharmacological targeting of the Keap-1−Nrf2 system has been investigated as a therapeutic strategy.20 Despite the known protective effect of Nrf2, few studies have assessed its potential to improve stem cell therapy. The effect of Nrf2 modulation was explored in a study in which Nrf2-overexpressing neuronal progenitor cells were transplanted into the striatum, which resulted in enhanced neuroprotective effects.21 Nrf2 plays a role in the regulation of cell fate determination in hematopoietic stem cells.22 Nrf2 activation by SIRT6 was shown to protect stem cells from oxidative stress-associated decay, revealing a mechanism by which SIRT6 forms a complex with Nrf2 and RNA polymerase II that is required for the expression of HO-1.23 Nrf2-overexpressing MSCs produce high levels of antioxidants, including SOD and HO-1, and show reduced apoptosis in response to oxidative stress, suggesting that Nrf2 overexpression could be a strategy for the prevention of graft cell death in MSC-based cell therapy.24 Our results support the modulation of the Keap-1−Nrf2 system as a strategy to improve the effect of ADSCs on fat grafts, as the effects of ADSCs on the viability and neovascularization of fat grafts, the production of NOX1/4 and HO-1, and ROS generation were reversed in the absence of Nrf2. Nrf2-activating compounds are currently being tested in clinical trials or are already in clinical use, such as dimethyl fumarate (Tecfidera), an Nrf2 pathway inhibitor used for the treatment of multiple sclerosis.25 Further studies are necessary to examine whether Nrf2 overexpression or activation of the Nrf2/Keap-1 system could improve the effect of ADSCs on the viability of fat grafts.

Assessment of fat transplants in our mouse model showed that ADSCs increased the vascularization of transplanted adipose tissue, upregulated VEGF and decreased ROS production, and these effects were dependent on TLR4 and Nrf2 expression. The increase in the number of capillaries induced by ADSC enrichment was partially suppressed by TLR4 and Nrf2 deletion. Nrf2 was previously shown to play an important role in the maintenance of the endothelial phenotype and the functional integrity of the vasculature.26,27 Redox signaling pathways and ROS play a central role in angiogenesis and VEGF-mediated signal transduction.28,29 VEGF increases ROS production in endothelial cells by activating NOX enzymes, and increased ROS activates Nrf2 by facilitating its dissociation from Keap-1, highlighting the role of Nrf2 in the regulation of angiogenesis via VEGF.30,31 Nrf2 silencing impairs the angiogenic process in VEGF-stimulated human coronary arterial endothelial cells in vitro, impairing migration and the ability of cells to form capillary-like structures, demonstrating the essential role of Nrf2 in angiogenesis.30 Furthermore, Nrf2 is involved in angiogenic growth factor signaling by regulating the activity of the serine/threonine kinase domain of growth factor receptors or by modulating HIF-1α-dependent pathways, illustrating the role of...
Figure 6  Nrf2 and TLR4 modulate ADSC apoptosis and ADSC-induced angiogenesis under conditions of hypoxia. ADSCs were isolated from WT, Nrf2−/− or TLR4−/− mice and cultured under normoxic or hypoxic conditions. (a) The effect of Nrf2 and TLR4 on hypoxia-induced apoptosis in ADSCs was analyzed by FITC-Annexin V and PI at 72 h after induction in hypoxia. In each panel, the Q4 (lower left) quadrant represents normal cells (untreated cells), the Q3 (lower right) quadrant contains early apoptotic cells (positive for AV and negative for PI), the Q2 (upper right) quadrant contains late apoptotic cells (positive for AV and positive for PI) and the Q1 (upper left) quadrant contains necrotic cells (negative for AV and positive for PI). (b) Quantification of the rate of Annexin V-positive cells at 72 h in hypoxia-induced ADSCs. Data represent the mean ± S.E.M. from three replicate experiments determined by the Student’s t-test. (c) Western blot detection of caspase-3 and cleaved caspase-3 in ADSCs cultured for 72 h in normoxic or hypoxic conditions; GAPDH was used as the loading control. Blot is a representative of three experiments. ***P<0.001 versus the control group, and ##P<0.01, ###P<0.001 versus the hypoxia control group. (d–g) The effect of Nrf2 and TLR4 deletion on EPC migration and angiogenesis induced by paracrine release from ADSCs cultured under hypoxia was evaluated. (d) Representative images of migrated EPCs in response to conditioned media (CM) from ADSCs or EBM (negative control). (magnification, × 200). Scale bar: 10 μm. (e) Percentage of migrated EPCs toward CM. (f) CM from hypoxia-induced ADSCs led to the formation of interconnected tubular structures by EPCs (magnification, × 200). Scale bar: 20 μm. (g) The number of branch points formed by EPCs in response to CM in all groups. **P<0.01, ***P<0.001 versus EBM; ###P<0.001 versus normal-ADSC-CM only
hypoxia in the induction of Nrf2-dependent pathways.\textsuperscript{32,33}

The role of hypoxia in the regulation of ADSC differentiation and viability by Nrf2 and TLR4 was assessed in the present study by subjecting ADSCs to hypoxia/serum deprivation conditions to simulate ischemic conditions. Our results showed that hypoxia enhanced the proliferation of ADSCs and their differentiation in response to different induction media. ADSCs cultured under hypoxic conditions showed increased inflammatory cytokine and growth factor receptor expression and increased ROS production, and these effects were dependent on Nrf2 and TLR4 expression. Nrf2 knockout enhanced hypoxia-induced inflammatory cytokine expression, ROS production and apoptosis in ADSCs, whereas TLR4 knockout inhibited them, and both Nrf2 and TLR4 knockout
suppressed the increase in growth factor levels induced by hypoxia. Furthermore, ADSCs promoted EPC migration and angiogenesis under conditions of hypoxia, and this effect was inhibited by Nrf2 and TLR4 deletion, indicating the involvement of the crosstalk between Nrf2 and TLR4 in hypoxia-induced EPC chemotaxis. TLR signaling can be affected by the cellular redox state, and Nrf2 plays an important role in ROS-mediated TLR4 activation and in modulating TLR4-driven inflammatory responses.\textsuperscript{34–36} Nrf2 and TLR4 are linked in the regulation of innate immune responses, as Nrf2 maintains redox homeostasis during sepsis and restrains the dysregulation of proinflammatory signaling pathways.\textsuperscript{37} Both TLR and Nrf2 signaling are activated during inflammation, and TLRs trigger Nrf2 signaling in response to inflammation; however, little is known about the crosstalk between these innate immune components. A recent study showed that TLR signaling activates the Nrf2 pathway by promoting Keap-1 degradation through the autophagy pathway.\textsuperscript{38} TLR-7 activation was shown to result in Nrf2-mediated antioxidant protection against ROS through myeloid differentiation primary response gene 88, a TLR adaptor protein that activates NF-κB.\textsuperscript{39}

The effect of hypoxia on enhancing the viability and regenerative potential of ADSCs has been shown previously, and culture of ADSCs under hypoxic conditions increases their proliferation, migration and growth factor secretion.\textsuperscript{11,12,40} The stimulatory effect of hypoxia on ADSCs is partially mediated by the production of ROS,\textsuperscript{41} and ROS generated through the action of NOX enzymes are involved in redox signaling associated with stem cell mobilization and proliferation.\textsuperscript{42} In addition, VEGF, which functions in angiogenesis, is regulated by ROS and acts as a paracrine mediator of ADSC function.\textsuperscript{41} Our results suggest that modulation of Nrf2 and TLR4 signaling could be developed as a strategy to improve the angiogenic potential of ADSCs and thus increase their efficiency for use in regenerative medicine.

TLR4 signaling cascades lead to the activation of NF-κB and the induction of proinflammatory cytokines and chemokines,\textsuperscript{17} and hypoxia plays an important role in the modulation of NF-κB activity and the inflammatory response.\textsuperscript{43} Our results showed that hypoxia activated NF-κB signaling and this effect was enhanced by Nrf2 deletion. Furthermore, silencing of NF-κB promoted Nrf2 nuclear translocation and antioxidant responses under conditions of hypoxia. Taken together, these results suggest that crosstalk between Nrf2 and NF-κB dependent signaling pathways modulates hypoxia-induced inflammation in ADSCs. These results support the potential of Nrf2 modulation to improve ADSC viability.

The present results led us to propose a model to explain the involvement of TLR4 and Nrf2 in the modulation of inflammation and oxidative stress related responses in ADSCs. In this model, inflammatory stimuli and oxidative stress stimulate TLR4 signaling and NF-κB mediated expression of inflammatory cytokines, leading to the activation of NOX enzymes and the generation of ROS. TLR4 activation and ROS generation promote Nrf2 nuclear translocation and antioxidant responses while inhibiting NF-κB signaling and inflammatory responses. Taken together, our results suggest a potential mechanism underlying the effects of inflammation and oxidative stress on ADSC viability and function via crosstalk between Nrf2, TLR4 and the NF-κB signaling pathway. These results provide insight into the pathways regulating the responses of ADSCs to the transplantation microenvironment, which may be of value for the design of strategies based on the use of ADSCs in cell therapy.

**Materials and Methods**

**Reagents.** Antibodies against KDR, CD29, CD90, CD44, CD105, CD34, Von Willenbrand factor (vWF), GAPDH, NOX1, NOX4, HO-1, TLR4, MyD88, TRAF6, NFkB P65, p-NFkB, Keap-1, Nrf2 and 2′,7′-dichlorofluorescein diacetate (DCF-DA) were obtained from Sigma (St Louis, MO, USA). DMEM (high glucose), serum-free EBM, and fetal bovine serum (FBS) were from Nego (Shanghai, China). Cell lysis buffer (10 x) was obtained from Cell Signaling Technology (CST, Boston, USA). The RT-PCR kit was purchased from TOYOBO (Shanghai, China). Other reagents included DAPI (Roche, Basel, Germany), hematoxylin and eosin (H&E; Toronto Chemicals, Toronto, ON, Canada), and trypsin (Sigma). All pairs of real-time PCR primers were synthesized by Shenggong Biotechnology (Shanghai, China). Other chemicals and reagents were of analytical grade.

**Animals and ethical statement.** WT and Nrf2−/− C57BL6 mice were kindly provided by Dr. Masayuki Yamamoto from Tohoku University of Riken Research Center. TLR4−/− (TLR4−/−) C57BL10 mice were purchased from the Model Animal Research Center of Nanjing University (MARC). Six-week-old WT, TLR4−/− and Nrf2−/− mice were used in this study. All animals were treated in accordance with the Guide for the Care and Use of Laboratory Animals, and all experiments were approved and performed according to the guidelines of the Ethics Committee of Union Hospital of Fujian Medical University, Fuzhou, Fujian, China.

**Isolation, culture and identification of ADSCs.** AD-MSCs were isolated as previously described.\textsuperscript{44} In brief, adipose tissue was harvested from normal, TLR4−/− and Nrf2−/− mice. Then, the tissue was washed with phosphate-buffered saline (PBS) and mechanically chopped before digestion with 0.2% collagenase I (Sigma) for 1 h at 37 °C with intermittent shaking. The digested tissue was washed with Dulbecco’s modified Eagle’s medium (DMEM) (Sigma) containing 15% FBS, and then centrifuged at 1000 r.p.m. for 10 min to remove mature adipocytes. The cell pellet was resuspended in DMEM supplemented with 15% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin in a 37 °C incubator with 5% CO2. ADSCs reaching 80–90% confluency were detached with 0.02% trypsinization. Cell numbers of ADSCs were determined using a hemocytometer. Cells were resuspended in 10 ml of control medium, and then re-plated at a density of 1 × 10^5 cells/dish. Three dishes were placed under normoxia conditions and another three in each group (contain normal, Nrf2−/− and TLR4−/− groups) under hypoxic conditions. The cells were allowed to proliferate for 5 days (P1–P8) and samples were harvested with 0.05% trypsinization. Cell numbers of ADSCs were determined using a hemocytometer. Cells were resuspended in 10 ml of control medium, and then re-plated at a density of 1 × 10^5 cells/dish; the procedure was repeated with hypoxic cells under hypoxia and with normoxic cells under normoxia from day 0 to 40, and cell numbers were determined at harvest for each 5 days.

**ELISA for soluble inflammatory cytokines and growth factors.** The amounts of IL-6, IL-1β, VEGF and bFGF in the supernatants of ADSCs or serum from mice with or without a fat graft were measured using commercially available ELISA kits (Sen-Xiong Company, Shenzhen, China). In accordance with the manufacturer’s instructions, supernatants were stored at –80 °C before measurement and both standards and samples were run in triplicate. OD450 was calculated by subtracting the background, and standard curves were plotted.
Fat graft implantation. Inguinal fat pads were harvested and tissues were processed as described above. Adipose tissues (0.5 ml) with or without the addition of ADSCs (0.3 ml adipose tissue+0.2 ml ADSCs/GFP-ADSCs at 5 × 10⁴ cells/ml) were used for fat grafts in the corresponding genotype mice. Mice were aged 6 weeks regardless of gender. All surgical tools were sterilized prior to surgery. A No. 16 syringe needle (Shifeng, Chengdu, China) was used to inject 0.5 ml of fat particles subcutaneously into two recipient sites on the back of experimental mice. After the operation, mice were cared for at the animal center (SFF level) of Union Hospital of Fujian Medical University, Fuzhou, Fujian, China.

Measurement of transplanted fat tissue ROS generation. For fat tissues, a DHE fluorescent probe was used for detecting ROS generation. Frozen sections were fixed with iced acetone at 4°C for 1 h. The sections were washed with PBS and incubated with the 10 μM DHE fluorescent probe for 1 h at 37°C. Tissue sections were visualized with a fluorescence microscope (ECLIPSE E600; Nikon, Tokyo, Japan). For cells, after the different pre-treatments, DCF-DA (10 μM) was added to the medium for 30 min; cells were incubated at 37°C in the dark, and then washed immediately with PBS. Fluorescent images of the cells were examined for the detection of ROS production with a fluorescence microscope (ECLIPSE E600; Nikon). The fluorescence intensity of DCF-DA was measured and calculated using flow cytometry (FlowJo, Ashland, OR, USA).

Differentiation assays. ADSCs between 1 and 20 days were plated at a density of 3 x 10⁴ cells/cm² on culture dishes in conditioned medium (CM). After 24 h, the medium was removed and cells were rinsed twice with DPBS. Adipogenic and endothelial differentiation were induced by culturing ADSCs for 1 or 3 weeks in Adipogenic Differentiation Media, Endothelial Differentiation Media and Osteogenic Differentiation Media (Cellular Engineering Technologies Inc., Coralville, IA, USA); Oil-red O and the Lipid Assay Kit (Primary Cell Co., Ltd, Hangzhou, China) were used to analyze the differentiation of ADSCs into adipocytes. Quantification of fat drops was performed using the Lipid Assay kit. Endothelial cell differentiation was determined by WVF immunofluorescence staining. The Alkaline Phosphatase (ALP) Assay Kit (Primary Cell Co.) was used according to the manufacturer’s instructions.

Apoptosis assay. Apoptosis of ADSCs was measured by flow cytometry. ADSCs were harvested and resuspended in 500 μl of binding buffer. Cells were then incubated with 5 μl annexin V-FITC and 5 μl propidium iodide (BD Biosciences, San Jose, CA, USA) at room temperature in the dark for 15 min. Subsequently, the samples were analyzed by flow cytometry using a FACSCalibur flow cytometer and FlowJo software (Flowjo).

Chemotaxis effect assays. Cell chemotaxis assays were performed using Transwell chambers as described previously. Briefly, ADSCs and EPCs were seeded at a density of 2 x 10⁵ cells/well in six-well plates. After 48 h of incubation, EPCs were trypsinized and resuspended in EBM. For the migration assay, a total of 1 x 10⁵ cells were added to the top chamber of prewetted Transwell inserts (BD Falcon 8 μm control insert). After incubation for 16 h (migration assay), cells were washed, fixed with 10% formaldehyde for 20 min and stained with 0.5% crystal violet. Cells that did not migrate through the pores were mechanically removed using a cotton swab. The images of migrated cells were acquired using an inverted microscope with a magnification of x200. The number of migrated cells was counted from five or six randomly selected fields in a blind manner. All migration experiments were performed in triplicate and repeated three times.

Evaluation of the angiogenic potential of ADSCs and the effect on EPCs under hypoxic conditions. To assess the effect of ADSCs on EPC tube formation under conditions of hypoxia, 1 x 10⁴ EPCs and 1 x 10⁴ ADSCs were mixed and resuspended in serum-free EB. Then seeded on Matrigel (around 50 μl of Matrigel) in cold wells (maintained at 4°C) in a 96-multiwell plate. After Matrigel jellification at 37°C for 30 min, cells were seeded at a concentration of 2 x 10⁵ cells/well in 50 μl. On days 1, 2 and 5 after seeding, the number of tubes formed was counted at x10 magnification by inverted microscopy.

Statistical analysis. Results are expressed as mean ± standard deviation (S.D.). Statistical significance was evaluated by analysis of variance followed by Tukey–Kramer multiple comparison test and by Student’s t-test. A P-value of < 0.05 denotes statistical significance.

Conflict of Interest
The authors declare no conflict of interest.

Acknowledgements. This study was supported by the National Natural Science Foundation of China (grant no. 81372092, Fujian Municipal Natural Science Foundation (grant no. 2016Y4003, Fujian Health Department Foundation (grant no. 2013-ZQN-ZD-15), Fujian Finance Department Foundation-Grant (grant no. 2020320) and key Program of National Clinical Specialty Discipline Construction of China.

1. Modaresi A. Platelet rich plasma (PRP) improves fat grafting outcomes. World J Plast Surg 2013; 2: 6–13.
2. Tabit CJ, Stack GC, Fan K, Wan DC, Bradley JP. Fat grafting versus adipose-derived stem cell therapy: distinguishing indications, techniques, and outcomes. Aesthetic Plast Surg 2012; 36: 704–713.
3. Kang HS, Choi SH, Kim BS, Choi JY, Park GB, Kwon TG et al. Advanced properties of urinary derived stem cells compared to adipose derived stem cells in terms of cell proliferation, immune modulation and multi differentiation. J Korean Med Sci 2015; 30: 1764–1776.

4. Kakagia D, Pallua N. Autologous fat grafting: in search of the optimal technique. Surg Innov 2011; 21: 327–336.

5. Langer S, Sintenis I, Eberhailer P, Krombach F, Messmer K. Revascularization of transplanted adipose tissue: a study in the dorsal skinfold chamber of hamsters. Ann Plast Surg 2002; 48: 33–39.

6. Karasoglu E, Kizilkaya E, Cermik H, Zienowicz R. The role of recipient sites in fat-graft survival: experimental study. Ann Plast Surg 2005; 55: 63–68; discussion 68.

7. Pazdro R, Harrison DE. Murine adipose tissue-derived stromal cell apoptosis and susceptibility to oxidative stress in vitro are regulated by genetic background. PLoS One 2013; 8: e61235.

8. Piccoli C, D’Aprile A, Scrima R, Ripoli M, Boffoli D, Tabilio A. The mechanism of ADSCs promote the survival of fat grafts. Cell Death and Disease 2016; 7: e2893.

9. Karacaoglu E, Kizilkaya E, Cermik H, Zienowicz R. The role of recipient sites in fat-graft survival: experimental study. Ann Plast Surg 2005; 55: 63–68; discussion 68.

10. Lee HY, Xie Y, Kim WS, Kim MH, Kim TH, Kim KJ et al. Nrf2-deficient mice. J Immunol 2010; 185: 569–577.

11. Lee JM, Li J, Johnson DA, Stein TD, Kraft AD, Calkins MJ. Hypoxia-induced mobilization of endothelial progenitor cells. Stem Cells Dev 2011; 20: 109–120.

12. Lee JM, Lijj J, Johnson DA, Stein TD, Kraft AD, Caikins MJ et al. Nrf2: a multi-origin protector? FASEB J 2005; 19: 1061–1066.

13. Leinonen HM, Kansanen E, Polonen P, Heinanen M, Levonen AL. Role of the Keap1-Nrf2 pathway in cancer. Adv Cancer Res 2014; 122: 281–320.

14. Caikins MJ, Vargas MR, Johnson DA, Johnson JA. Astrocyte-specific overexpression of Nrf2 protects striatal neurons from mitochondrial complex II inhibition. Toxicol Sci 2010; 115: 557–568.

15. Murakami S, Shimizu R, Romeo PH, Yamamoto M, Motohashi H. Keap1-Nrf2 system regulates cell fate determination of hematopoietic stem cells. Genes Cells 2014; 19: 239–253.

16. Pan JS, Guan D, Liu X, Li J, Wang L, Wu J et al. SIRT5 safeguards human mesenchymal stem cells from oxidative stress by coactivating NRF2. Cell Res 2016; 26: 190–205.

17. Mohammadianzadeh M, Halabian R, Gharaghahbini A, Amirzadeh N, Jahani-Najafabadi A, Roushandeh AM et al. Nrf2 overexpression in mesenchymal stem cells reduces oxidative stress-induced apoptosis and cytotoxicity. Cell Stress Chaperones 2012; 17: 553–565.

18. Venci M, Gandhi MA. Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis. Ann Pharmacother 2013; 47: 1697–1702.

19. Zakkat M, Van der Heiden K, Luong A, Chaudhury H, Cuhlnmann S, Hamdulay SS et al. Activation of Nrf2 in endothelial cells protects arteries from exhibiting a proinflammatory state. Arterioscler Thromb Vasc Biol 2009; 29: 1851–1857.

20. Jyrkkonen HK, Kansanen E, Inkala M, Kivelä AM, Hurttila H, Heinonen SE et al. Nrf2 regulates antioxidant gene expression evoked by oxidized phospholipids in endothelial cells and murine arteries in vivo. Circ Res 2008; 103: e1–e9.

21. Usheio-Fukai M, Nakamura Y. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett 2008; 266: 37–52.

22. Abid MR, Spokes KC, Shih SC, Aird WC. NADPH oxidase activity selectively modulates vascular endothelial growth factor signaling pathways. J Biol Chem 2007; 282: 35373–35385.

23. Valcarcel-Ares MN, Gautam T, Warrington JP, Bailey-Downs L, Sosnowska D, de Cabo R et al. Disruption of Nrf2 signaling impairs angiogenic capacity of endothelial cells: implications for microvascular aging. J Gerontol A Biol Sci Med Sci 2012; 67: 821–829.

24. Carriere A, Ebrahimian TG, Dehez S, Auge N, Joffre C, Andre M. Impaired liver regeneration in Nrf2 knockout mice: role of ROS-mediated insulin/IGF-1 resistance. EMBO J 2006; 25: 212–223.

25. Loboda A, Stachurska A, Florczyk U, Rudnicka D, Jazwa A, Wegorzyn J et al. HIF-1 induction attenuates Nrf2-dependent IL-8 expression in human endothelial cells. Antioxid Redox Signal 2009; 11: 1501–1517.

26. West AP, Brodsky IE, Rahner C, Woo DK, Erdjument-Bromage H, Tempst P et al. TLR signaling augments macrophage bactericidal activity through mitochondrial ROS. Nature 2011; 472: 476–480.

27. Kong X, Thimmulappa R, Kambairua P, Biswal S. NADPH oxidase-dependent reactive oxygen species mediate amplified TLR4 signaling and sepsis-induced mortality in Nrf2-deficient mice. J Immunol 2010; 185: 569–577.

28. Reddy NM, Suryanarayana V, Kalakolamvu D, Yamamoto M, Kessler TW, Hassoun PM et al. Innate immunity against bacterial infection following hypoxia exposure is impaired in Nrf2-deficient mice. J Immunol 2009; 183: 4601–4608.

29. Thimmulappa RK, Lee H, Rangasamy T, Reddy SP, Yamamoto M, Kessler TW et al. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest 2006; 116: 984–995.

30. Yin S, Cao W. Toll-like receptor signaling induces Nrf2 pathway activation through p62-triggered Keap1 degradation. Mol Cell Biol 2015; 35: 2673–2683.

31. Nadeem A, Siddiqui N, Al-Harbi NO, Al-Harbi MM, Ahmad SF. TLR-7 agonist attenuates airway reactivity and inflammation through Nrf2-mediated antioxidant protection in a murine model of allergic asthma. Int J Biochem Cell Biol 2016; 73: 53–62.

32. Chung HM, Won CH, Sung JH. Responses of adipose-derived stem cells during hypoxia: enhanced skin-regenerative potential. Expert Opin Biol Ther 2009; 9: 1499–1508.

33. Kim JH, Park SH, Park SG, Choi JS, Xia Y, Sung JH. The pivotal role of reactive oxygen species generation in the hypoxia-induced stimulation of adipose-derived stem cells. Stem Cells Dev 2011; 20: 1753–1761.

34. Schroder K, Kohnen A, Aicher A, Liehn EA, Buchse T, Stein S et al. NADPH oxidase Nox2 is required for hypoxia-induced mobilization of endothelial progenitor cells. Circ Res 2009; 105: 537–544.

35. Biddestone J, Bandara D, Rocha S. The role of hypoxia in inflammatory disease (review). Int J Mol Sci 2015; 16: 8595–8609.

36. Yamamoto Y, Fujita M, Tanaka Y, Kojima I, Kanatani Y, Ishihara M et al. Impaired HIF-1 induction attenuates VEGF overexpression in rat cardiac myocytes. J Appl Physiol 2010; 108: 525–532.

37. Deveza L, Choi J, Balakriev G, Yang F. Paracrine release from nonviral engineered mesenchymal stem cells impairs endothelial cell survival and migration in vitro. Stem Cells Dev 2013; 22: 483–491.

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/